Stereotactic body radiotherapy (SBRT) has shown positive outcomes in improving survival among patients with oligometastases. However, not many studies have analyzed its safety and efficacy in treating patients with multiple metastases. This study aims to determine the safety and efficacy of SBRT dose schedules in patients with numerous metastases.
This phase 1 open trial included a total of 35 eligible patients with prostate, non-small cell lung, and breast cancer with multiple metastases. The patients were assigned to a starting dose of 50 Gy in 5 fractions, 45 Gy in 3 fractions, and 30 Gy in 3 fractions. The primary outcome of the study was dose-limiting toxicity, along with adverse events.
Of 35 patients included in the study, 12 had breast cancer, 10 had non-small cell lung cancer, and 13 had prostate cancer, with a median of 3 metastases per patient. The median survival was not reached, and no protocol-defined dose-limiting toxicity was observed. A total of 8 instances of grade 3 adverse events related to protocol therapy were observed in 7 patients.
The trial concluded that SBRT was safe for patients with multiple metastases with no treatment-related deaths and a few late-grade adverse events. However, more research is required to demonstrate the efficacy of the therapy.
Ref: https://jamanetwork.com/journals/jamaoncology/article-abstract/2778658?resultClick=1
